Natco Pharam files ANDAs for USFDA approval

For Fingolimod, 0.5mg Capsules & Cabazitaxel, 60mg/1.5ml Injection

Natco Pharma announced that it has filed Abbreviated New Drug Applications (ANDAs) for Fingolimod, 0.5mg Capsules & Cabazitaxel, 60mg/1.5ml Injection, with the U.S. Federal Drug Administration (USFDA), through its respective marketing partners in the USA.

Powered by Capital Market - Live News